TARGET KRAS WITH CONFIDENCE
KRASmut PDO SCREEN
Test the efficacy of your compound(s) in a panel of more than 25 patient-derived organoids representing colorectal, lung, and pancreatic cancer
Colorectal
cancer
Lung
cancer
Pancreatic
cancer
Proven Impact
Our meticulously designed KRASmut panel was instrumental in developing the first-ever clinical candidate using organoid technology, targeting head & neck cancer
Panel features
- Largest commercially available KRASmut PDO panel including 28 models
- Representing pivotal KRAS mutants such as G12A, G12D, G12V, G13D and many others
- Rigorously characterized, with readily available RNA or DNA sequencing data
- Diverse models encompassing both primary and metastatic tumors
- Test off-tumor toxicities with matched normal organoids
- The most competitive pricing on the market when choosing a full panel screen
Advanced screening capabilities
- Direct measurement of cell viability with an image-based viability readout
- High-throughput 3D assay format
- Test as many compound(s) as you want
- No minimum number of models to enroll
- High-data quality with 10-point dose-response curves per compound
- Inclusive of IC50 determination and IC50 heatmap generation
| Screen slot | Registration deadline | Study initiation |
|---|---|---|
|
October
 |
September 13th | October 15th |
|
November
 |
October 15th | November 14th |
| December | November 14th | December 5th |
Test your compound on our adagrasib resistant PDO for free
Valid for any study of more than 4 PDOs
Accelerate your KRAS drug development with our comprehensive portfolio
Identify promising leads
Benchmark against standard of care
Understand the mechanism of action
Investigate resistance mechanisms
Craft optimal combination
therapy
therapy
Develop co-clinical
biomarker assays
biomarker assays
Companion
diagnostics partnering
diagnostics partnering